Dane Leone

Mr. Leone brings 20 years of experience as a leading equity research analyst to Xencor, where he supports the Company’s R&D leadership to enhance value across Xencor’s platform technologies by overseeing assessment and prioritization of Xencor’s current and future XmAb® drug candidates. Mr. Leone most recently served as a managing director and senior biotechnology analyst at Raymond James. Mr. Leone’s focus areas in equity research included oncology, immunology, cardiology and ophthalmology. His coverage spanned securities across a wide range of market capitalization, from biotechnology companies advancing a diverse set of drug candidates to commercializing novel medicines. Before Raymond James, Mr. Leone held analyst roles with increasing seniority at BTIG and Macquarie Securities Group. He began his career in portfolio management as a health care and quantitative research analyst at AllianceBernstein. Mr. Leone received his B.S. in business from the State University of New York at Albany. He holds the Chartered Financial Analyst® designation from the CFA® Institute.

CFA® and Chartered Financial Analyst® are registered trademarks of CFA Institute.